A study of the microbiology of diabetic foot infections in a teaching hospital in Kuwait

Journal of Infection and Public Health
Khalifa Al BenwanVincent O Rotimi

Abstract

The purpose of this study was to determine the microbiological profile of diabetic foot infections (DFIs) and assess the antibiotic susceptibility of the causative agents. Data were obtained from a retrospective analysis of DFI samples collected from June 2007 to July 2008. Specimens were cultured using optimal aerobic and anaerobic microbiological techniques, and antibiotic susceptibility testing was performed according to the methods recommended by the Clinical and Laboratory Standards Institute (CLSI). Extended-spectrum β-lactamase (ESBL) production was measured using the double disk synergy test and the ESBL Etest. A total of 440 patients were diagnosed with DFIs during this period, and a total of 777 pathogens were isolated from these patients with an average of 1.8 pathogens per lesion. We isolated more Gram-negative pathogens (51.2%) than Gram-positive pathogens (32.3%) or anaerobes (15.3%). Polymicrobial infection was identified in 75% of the patients. The predominant organisms isolated were members of the Enterobacteriaceae family (28.5%), Pseudomonas aeruginosa (17.4%), Staphylococcus aureus (11.8%), methicillin-resistant S. aureus (7.7%), anaerobic Gram-negative organisms (10.8%), and Enterococcus spp. (7%). Vancomyc...Continue Reading

References

Mar 31, 1999·Diabetes Care·S D RamseyE H Wagner
Oct 12, 2000·Diabetes Research and Clinical Practice·A Zaini
May 10, 2003·Lancet·William J Jeffcoate, Keith G Harding
Dec 20, 2003·American Journal of Surgery·Robert G Frykberg
May 20, 2004·Diabetes/metabolism Research and Reviews·Benjamin A Lipsky, UNKNOWN International consensus group on diagnosing and treating the infected diabetic foot
Oct 9, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Benjamin A LipskyUNKNOWN Infectious Diseases Society of America
May 4, 2005·Journal of Diabetes and Its Complications·Adel AbdulrazakLubna Ahmed Mobasher
Jul 11, 2006·Journal of Clinical Microbiology·Yumi A WarrenEllie J C Goldstein
Jul 5, 2007·Journal of Clinical Microbiology·Diane M CitronMurray A Abramson
Jun 5, 2008·Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre·Mohamed A A MoussaJoseph E Gomez

❮ Previous
Next ❯

Citations

Jan 24, 2014·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M HatipogluB A Lipsky
Oct 21, 2014·Annals of Medical and Health Sciences Research·Sm SekharC Mukhopadhyay
Aug 21, 2014·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·Liza BraunLawrence A Lavery
Dec 9, 2015·Journal of Diabetes and Its Complications·Alejandra Bravo-MolinaJosé Hernández-Quero
Apr 10, 2013·Expert Review of Anti-infective Therapy·Lyudmila Boyanova, Ivan Mitov
Mar 12, 2016·Journal of Diabetes and Its Complications·Mustafa HatipogluGonul Sengoz
May 7, 2013·Diabetes Research and Clinical Practice·Azadeh ZabetianMohammed K Ali
Aug 6, 2013·Diabetes, Obesity & Metabolism·I UçkayB A Lipsky
Apr 7, 2015·Anaerobe·Patrick G P CharlesBenjamin A Lipsky
Mar 31, 2015·Journal of the American Podiatric Medical Association·Heather YoungConnie S Price
Oct 8, 2014·The International Journal of Lower Extremity Wounds·Besa ZenelajIlker Uçkay
Dec 19, 2017·Journal of the American Podiatric Medical Association·Bulent M ErtugrulSerhan Sakarya
Jun 5, 2018·International Wound Journal·Steven L PercivalGregory Schultz
Sep 20, 2019·The International Journal of Lower Extremity Wounds·Prakhar Srivastava, Karthikeyan Sivashanmugam
Jul 7, 2017·The International Journal of Lower Extremity Wounds·Mario Sánchez-SánchezVirgilio Bocanegra-García
Nov 14, 2019·Journal of Clinical Medicine·Fatemah Sadeghpour HeraviHonghua Hu
Aug 12, 2020·International Wound Journal·Lamia JouharJamal J Hoballah
Dec 31, 2020·PloS One·Asma AlhubailAli Tiss
Apr 8, 2021·African Journal of Laboratory Medicine·Adeyemi T AdeyemoAaron O Aboderin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.